Naltrexone for the treatment of obesity: review and update
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Since their discovery in the brain and gastrointestinal tract nearly 40 years ago, endogenous opioid peptides have been progressively shown to play a role in the regulation of food intake. Animal and human studies regarding opioid peptides and ingestive behavior are reviewed. While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583 · cited 1×
“Such activation leads to autoinhibitory opioid feedback; POMC cleavage produces the endogenous opioid β-endorphin, which inhibits POMC neurons [25].”
BackgroundBupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315 · cited 1×
“As shown in Figure 1, such weight loss is modest (5 – 10%) and non-progressive, reaching a plateau after ∼ 6 months of therapy [26].”
BackgroundSelf-citation
Cited by
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Deal, C. L., Tony, M., Höybye, C., Allen, D. B., Tauber, M., Christiansen, J. S., & Participants, T. 2. G. H. I. P.-W. S. C. C. G. W. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3888 · Cited by 379
Drug treatment of obesity: Current status and future prospects
Kakkar, A. K., & Dahiya, N. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.01.005 · Cited by 113
“However, minimal weight loss induced by themonotherapy further lead to exploration of its combination with POMC activator bupropion for the treatment of obesity [43].”
BackgroundHaney, M., Ramesh, D., Glass, A., Pavlicova, M., Bedi, G., & Cooper, Z. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.108 · Cited by 73
Metadata
- Authors
- Lee, M. W., & Fujioka, K.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2009-06-18
- Volume
- 10
- Issue
- 11
- Pages
- 1841-1845
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1975933615
- Cited by
- 49
- References
- 2
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone for the treatment of obesity: review and update. https://app.cochat.ai/papers/10.1517/14656560903048959
- The paper
- Lee, M. W., & Fujioka, K. (2009). Naltrexone for the treatment of obesity: review and update. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656560903048959
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.